Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

Analyst recommends Novartis as a Buy for long-term investors, BioAge a Hold, following strategic partnership for age-related ...

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Fractyl Health, Inc. (GUTS – Research Report). The associated price ...

Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain investment potential to beef up your portfolio.

The MHRA warns against buying weight-loss medicines illegally, emphasizing health risks and the need for prescriptions from ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued sales growth ...

Some of my weight loss medicine colleagues who have more experience than I do note that some people do better with semaglutide, whereas others do better with another GLP-1 agonist, tirzepatide.